In Reply: Neoadjuvant TKI Study in Early- and Intermediate Stage Hepatocellular Carcinoma
This letter to the editor responds to comments from Rizzo et al on recently reported results of a phase II study of dovitinib therapy for hepatocellular carcinoma.
Gespeichert in:
| Veröffentlicht in: | The oncologist (Dayton, Ohio) Ohio), 2022-12, Vol.27 (12), p.e977-e978 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e978 |
|---|---|
| container_issue | 12 |
| container_start_page | e977 |
| container_title | The oncologist (Dayton, Ohio) |
| container_volume | 27 |
| creator | Osanto, Susanne Woei-A-Jin, F J Sherida H Coenraad, Minneke J Weijl, Nir I Burgmans, Mark C Burggraaf, Jacobus |
| description | This letter to the editor responds to comments from Rizzo et al on recently reported results of a phase II study of dovitinib therapy for hepatocellular carcinoma. |
| doi_str_mv | 10.1093/oncolo/oyac215 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9732251</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A780547345</galeid><sourcerecordid>A780547345</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-9d551db72678199a4660af6a46f7731757c75f4a238be103700f2251c5e993f23</originalsourceid><addsrcrecordid>eNptkc9rFTEQx4MotlavHiXgxcu2-bHZbDwI5VHbh0VBK-gpzMsmz5Rs8prdLex_b5b3WhTKHGaY-cyXGb4IvaXklBLFz1I0KaSzNINhVDxDx1TUqqoV-fW81KTllaRCHaFXw3BLSCk5e4mOeMMaRRt5jH6vI_5ud2H-iL_aBN3tdA9xxDdf1vjHOHUz9hFfQA5zhSF2eB1Hm3vbeRhtAWBr8ZXdwZiMDWEKkPEKsvEx9fAavXAQBvvmkE_Qz88XN6ur6vrb5Xp1fl2ZmrKxUp0QtNtI1siWKgV10xBwTclOSk6lkEYKVwPj7cZSwiUhjjFBjbBKccf4Cfq0191Nm3KZsXHMEPQu-x7yrBN4_f8k-j96m-61knwRKgIfDgI53U12GHXvh-UfiDZNg2aSyaZmrRQFfb9HtxCs9tGlomgWXJ_Lloha8nqhTp-gSnS29yZF63zpP7VgchqGbN3j9ZToxWa9t1kfbC4L7_79-RF_8JX_BTREpFs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2727642875</pqid></control><display><type>article</type><title>In Reply: Neoadjuvant TKI Study in Early- and Intermediate Stage Hepatocellular Carcinoma</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford Journals Open Access Collection</source><source>PubMed Central</source><creator>Osanto, Susanne ; Woei-A-Jin, F J Sherida H ; Coenraad, Minneke J ; Weijl, Nir I ; Burgmans, Mark C ; Burggraaf, Jacobus</creator><creatorcontrib>Osanto, Susanne ; Woei-A-Jin, F J Sherida H ; Coenraad, Minneke J ; Weijl, Nir I ; Burgmans, Mark C ; Burggraaf, Jacobus</creatorcontrib><description>This letter to the editor responds to comments from Rizzo et al on recently reported results of a phase II study of dovitinib therapy for hepatocellular carcinoma.</description><identifier>ISSN: 1083-7159</identifier><identifier>EISSN: 1549-490X</identifier><identifier>DOI: 10.1093/oncolo/oyac215</identifier><identifier>PMID: 36269167</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Carcinoma, Hepatocellular - drug therapy ; Humans ; Letter to the Editor ; Liver Neoplasms - drug therapy ; Neoadjuvant Therapy</subject><ispartof>The oncologist (Dayton, Ohio), 2022-12, Vol.27 (12), p.e977-e978</ispartof><rights>COPYRIGHT 2022 Oxford University Press</rights><rights>The Author(s) 2022. Published by Oxford University Press. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c412t-9d551db72678199a4660af6a46f7731757c75f4a238be103700f2251c5e993f23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732251/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732251/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,862,883,27913,27914,53780,53782</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36269167$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Osanto, Susanne</creatorcontrib><creatorcontrib>Woei-A-Jin, F J Sherida H</creatorcontrib><creatorcontrib>Coenraad, Minneke J</creatorcontrib><creatorcontrib>Weijl, Nir I</creatorcontrib><creatorcontrib>Burgmans, Mark C</creatorcontrib><creatorcontrib>Burggraaf, Jacobus</creatorcontrib><title>In Reply: Neoadjuvant TKI Study in Early- and Intermediate Stage Hepatocellular Carcinoma</title><title>The oncologist (Dayton, Ohio)</title><addtitle>Oncologist</addtitle><description>This letter to the editor responds to comments from Rizzo et al on recently reported results of a phase II study of dovitinib therapy for hepatocellular carcinoma.</description><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Humans</subject><subject>Letter to the Editor</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Neoadjuvant Therapy</subject><issn>1083-7159</issn><issn>1549-490X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkc9rFTEQx4MotlavHiXgxcu2-bHZbDwI5VHbh0VBK-gpzMsmz5Rs8prdLex_b5b3WhTKHGaY-cyXGb4IvaXklBLFz1I0KaSzNINhVDxDx1TUqqoV-fW81KTllaRCHaFXw3BLSCk5e4mOeMMaRRt5jH6vI_5ud2H-iL_aBN3tdA9xxDdf1vjHOHUz9hFfQA5zhSF2eB1Hm3vbeRhtAWBr8ZXdwZiMDWEKkPEKsvEx9fAavXAQBvvmkE_Qz88XN6ur6vrb5Xp1fl2ZmrKxUp0QtNtI1siWKgV10xBwTclOSk6lkEYKVwPj7cZSwiUhjjFBjbBKccf4Cfq0191Nm3KZsXHMEPQu-x7yrBN4_f8k-j96m-61knwRKgIfDgI53U12GHXvh-UfiDZNg2aSyaZmrRQFfb9HtxCs9tGlomgWXJ_Lloha8nqhTp-gSnS29yZF63zpP7VgchqGbN3j9ZToxWa9t1kfbC4L7_79-RF_8JX_BTREpFs</recordid><startdate>20221201</startdate><enddate>20221201</enddate><creator>Osanto, Susanne</creator><creator>Woei-A-Jin, F J Sherida H</creator><creator>Coenraad, Minneke J</creator><creator>Weijl, Nir I</creator><creator>Burgmans, Mark C</creator><creator>Burggraaf, Jacobus</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20221201</creationdate><title>In Reply: Neoadjuvant TKI Study in Early- and Intermediate Stage Hepatocellular Carcinoma</title><author>Osanto, Susanne ; Woei-A-Jin, F J Sherida H ; Coenraad, Minneke J ; Weijl, Nir I ; Burgmans, Mark C ; Burggraaf, Jacobus</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-9d551db72678199a4660af6a46f7731757c75f4a238be103700f2251c5e993f23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Humans</topic><topic>Letter to the Editor</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Neoadjuvant Therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Osanto, Susanne</creatorcontrib><creatorcontrib>Woei-A-Jin, F J Sherida H</creatorcontrib><creatorcontrib>Coenraad, Minneke J</creatorcontrib><creatorcontrib>Weijl, Nir I</creatorcontrib><creatorcontrib>Burgmans, Mark C</creatorcontrib><creatorcontrib>Burggraaf, Jacobus</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The oncologist (Dayton, Ohio)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Osanto, Susanne</au><au>Woei-A-Jin, F J Sherida H</au><au>Coenraad, Minneke J</au><au>Weijl, Nir I</au><au>Burgmans, Mark C</au><au>Burggraaf, Jacobus</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In Reply: Neoadjuvant TKI Study in Early- and Intermediate Stage Hepatocellular Carcinoma</atitle><jtitle>The oncologist (Dayton, Ohio)</jtitle><addtitle>Oncologist</addtitle><date>2022-12-01</date><risdate>2022</risdate><volume>27</volume><issue>12</issue><spage>e977</spage><epage>e978</epage><pages>e977-e978</pages><issn>1083-7159</issn><eissn>1549-490X</eissn><abstract>This letter to the editor responds to comments from Rizzo et al on recently reported results of a phase II study of dovitinib therapy for hepatocellular carcinoma.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>36269167</pmid><doi>10.1093/oncolo/oyac215</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1083-7159 |
| ispartof | The oncologist (Dayton, Ohio), 2022-12, Vol.27 (12), p.e977-e978 |
| issn | 1083-7159 1549-490X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9732251 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford Journals Open Access Collection; PubMed Central |
| subjects | Carcinoma, Hepatocellular - drug therapy Humans Letter to the Editor Liver Neoplasms - drug therapy Neoadjuvant Therapy |
| title | In Reply: Neoadjuvant TKI Study in Early- and Intermediate Stage Hepatocellular Carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T09%3A22%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20Reply:%20Neoadjuvant%20TKI%20Study%20in%20Early-%20and%20Intermediate%20Stage%20Hepatocellular%20Carcinoma&rft.jtitle=The%20oncologist%20(Dayton,%20Ohio)&rft.au=Osanto,%20Susanne&rft.date=2022-12-01&rft.volume=27&rft.issue=12&rft.spage=e977&rft.epage=e978&rft.pages=e977-e978&rft.issn=1083-7159&rft.eissn=1549-490X&rft_id=info:doi/10.1093/oncolo/oyac215&rft_dat=%3Cgale_pubme%3EA780547345%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2727642875&rft_id=info:pmid/36269167&rft_galeid=A780547345&rfr_iscdi=true |